Clinical Trial Update: Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating solifenacin succinate (VESIcare) for overactive bladder symptoms in patients with Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder in Parkinson Disease

Drugs mentioned

• Solifenacin succinate (solifenacin)

Snippet

Sponsor: University of South Florida | Conditions: Overactive Bladder in Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-05-27